Does-Dependent Effects Of Rivaroxaban In Treatment Of Venous Hromboebolism

Objective To investigate the preliminary efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, in patients with venous thromboembolism (VTE). Methods Thirty three inpatients with VTE received rivaroxaban at the does of 15mg bid-1 for 21 days then 20mg qd-1, 20mg qd-1, 10mg qd-1 for 3 months. Patients were followed up for the reduction rate of D-Dimer in three days’ treatment, the length of D-Dimer reduced to normal, hospital stay and remission, the imaging assessment after the treatment for three month, recurrent VTE, bleeding, liver and kidney function. Results Compared with those in 20mg qd-1 group and 10mg qd-1 group, the reduction rates of D-Dimer in 15mg bid-1 for 21 days then 20mg qd-1 group were significantly higher (P=0.02, P=0.01), and the lengths of D-Dimer returned to normal were significantly shorter (P=0.03, P<0.01). There was one recurrent deep-vein thrombosis in 10mg qd-1 group, one non-major bleeding in 15mg bid-1 for 21days then 20mgqd-1 group and one in 10mgqd-1 group, one patient died due to right heart failure, no major bleeding and no dysfunction of liver and kidney. Conclusions Venous thromboembolism can be treated by rivaroxaban safely and efficaciously. D-Dimer can be reduced more quickly with the treatment of rivaroxaban 15mg bid-1.